Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.

Drug design, development and therapy - 1 Jan 2015

Bennett Lunawati L, Turcotte Kelsey

Abstract excerpt

The purpose of this article is to review eliglustat tartrate, a substrate reduction therapy, for the treatment of Gaucher disease type 1 (GD1). GD is an rare inborn error of metabolism caused by accumulation of lipid substrates such as glucosylceramide within the monocyte-macrophage system that affects the body by causing enlargement of the spleen and liver, destruction of bone, and abnormalities of the lungs and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Cytochrome P-450 CYP2D6
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Costs

Share to Gaucher Disease

Share to Glucosylceramides

Share to Glucosyltransferases

Share to Pyrrolidines

Source

Open in PubMed Open full text

Identifiers

PMID: 26345314
DOI: 10.2147/DDDT.S77760
PMCID: PMC4554398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.PMID 26345314Read ↗

Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.Semantic proximity Read ↗

Repurposing Gaucher disease therapy for Saposin C deficiency: Proof-of-concept with eliglustat.Semantic proximity Read ↗

Type 1 Gaucher disease (CYP2D6-eliglustat).Semantic proximity Read ↗

An Overview of Gaucher DiseaseSemantic proximity Read ↗

Recent advances in the diagnosis and management of Gaucher disease.Semantic proximity Read ↗

Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.Semantic proximity Read ↗

How I treat Gaucher disease.Semantic proximity Read ↗

Gaucher Disease: Clinical, Biological and Therapeutic AspectsSemantic proximity Read ↗

Gaucher's disease: a paradigm for interventional genetics.Semantic proximity Read ↗

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher diseaseSemantic proximity Read ↗

Gaucher disease.Semantic proximity Read ↗

Emerging therapeutic targets for Gaucher disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.